Airain ltd cut its holdings in shares of Merck & Company, Inc. (NYSE:MRK) by 1.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 235,757 shares of the company’s stock after selling 3,491 shares during the period. Merck & comprises about 0.7% of Airain ltd’s investment portfolio, making the stock its 27th biggest holding. Airain ltd’s holdings in Merck & were worth $15,110,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in the company. Shine Investment Advisory Services Inc. acquired a new position in Merck & in the first quarter worth about $361,000. Lourd Capital LLC grew its stake in Merck & by 44.6% in the first quarter. Lourd Capital LLC now owns 5,689 shares of the company’s stock worth $361,000 after purchasing an additional 1,754 shares in the last quarter. Bourgeon Capital Management LLC grew its stake in Merck & by 4.9% in the first quarter. Bourgeon Capital Management LLC now owns 92,215 shares of the company’s stock worth $5,859,000 after purchasing an additional 4,335 shares in the last quarter. Alerus Financial NA grew its stake in Merck & by 2.7% in the first quarter. Alerus Financial NA now owns 33,841 shares of the company’s stock worth $2,150,000 after purchasing an additional 890 shares in the last quarter. Finally, Vigilant Capital Management LLC grew its stake in Merck & by 16.7% in the first quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock worth $111,000 after purchasing an additional 250 shares in the last quarter. Institutional investors own 73.15% of the company’s stock.

A number of equities analysts recently commented on MRK shares. Jefferies Group LLC reiterated a “sell” rating and issued a $52.00 price target on shares of Merck & in a research note on Sunday, August 20th. BMO Capital Markets reissued a “buy” rating and issued a $72.00 target price on shares of Merck & in a report on Friday, September 8th. Credit Suisse Group cut their target price on shares of Merck & from $75.00 to $74.00 and set an “outperform” rating on the stock in a report on Wednesday, August 30th. SunTrust Banks, Inc. cut shares of Merck & from a “buy” rating to a “hold” rating in a report on Monday, October 30th. Finally, Cowen and Company reissued a “hold” rating and issued a $70.00 target price on shares of Merck & in a report on Friday, September 1st. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and ten have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $66.87.

TRADEMARK VIOLATION NOTICE: This article was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.thecerbatgem.com/2017/11/19/merck-company-inc-mrk-stake-decreased-by-airain-ltd.html.

Shares of Merck & Company, Inc. (NYSE:MRK) opened at $55.20 on Friday. Merck & Company, Inc. has a twelve month low of $54.40 and a twelve month high of $66.80. The company has a market capitalization of $150,388.92, a P/E ratio of 14.19, a P/E/G ratio of 2.38 and a beta of 0.78. The company has a current ratio of 1.43, a quick ratio of 1.16 and a debt-to-equity ratio of 0.57.

Merck & (NYSE:MRK) last announced its earnings results on Friday, October 27th. The company reported $1.11 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.08. Merck & had a return on equity of 27.08% and a net margin of 11.60%. The firm had revenue of $10.33 billion for the quarter, compared to analysts’ expectations of $10.54 billion. During the same quarter in the previous year, the company earned $1.07 earnings per share. The firm’s quarterly revenue was down 2.0% compared to the same quarter last year. analysts expect that Merck & Company, Inc. will post 3.95 EPS for the current year.

In related news, Director Thomas H. Glocer sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $56.20, for a total transaction of $281,000.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.25% of the stock is owned by insiders.

About Merck &

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Stock Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related stocks with our FREE daily email newsletter.